logo
  

ViiV Enters Collaboration And License Agreement With Shionogi To Develop HIV Integrase Inhibitor

ViiV Healthcare announced an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, an investigational integrase strand transfer inhibitor with potential for use in ultra long-acting HIV regimens. ViiV Healthcare and Shionogi plan to begin first time in human studies with S-365598 by 2023.

ViiV Healthcare will make an upfront payment of 20 million pounds to Shionogi, a 15 million pounds payment for the achievement of a clinical development milestone and royalties on net sales.

"With today's announcement about the in-licensing of a third integrase inhibitor from Shionogi, we will continue this collaboration and explore the potential of S-365598 to anchor ViiV Healthcare's pipeline beyond 2030," Kimberly Smith, Head of Research & Development at ViiV Healthcare said.

ViiV Healthcare is a global specialist HIV company majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT